Aduro BioTech Inc (NASDAQ:ADRO)’s share price rose 6.5% during mid-day trading on Friday . The stock traded as high as $6.70 and last traded at $6.60. Approximately 553,962 shares were traded during trading, an increase of 6% from the average daily volume of 522,221 shares. The stock had previously closed at $6.20.
ADRO has been the subject of several analyst reports. BidaskClub upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 23rd. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Oppenheimer started coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 price objective for the company. Finally, ValuEngine downgraded Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. Aduro BioTech currently has a consensus rating of “Buy” and a consensus price target of $17.38.
In other Aduro BioTech news, VP Jennifer Lew sold 6,600 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.46, for a total value of $62,436.00. Following the transaction, the vice president now owns 68,938 shares of the company’s stock, valued at $652,153.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stephen T. Isaacs sold 7,949 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $7.95, for a total value of $63,194.55. Following the completion of the transaction, the insider now directly owns 213,695 shares in the company, valued at approximately $1,698,875.25. The disclosure for this sale can be found here. Insiders sold 172,656 shares of company stock valued at $1,486,582 over the last 90 days. 6.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ADRO. Harvard Management Co. Inc. bought a new position in shares of Aduro BioTech in the third quarter valued at $69,418,000. Citadel Advisors LLC bought a new position in shares of Aduro BioTech in the fourth quarter valued at $1,309,000. Baillie Gifford & Co. increased its holdings in shares of Aduro BioTech by 30.8% in the third quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after buying an additional 130,390 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Aduro BioTech by 5.4% in the second quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after buying an additional 129,079 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Aduro BioTech by 52.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 294,007 shares of the biotechnology company’s stock valued at $2,205,000 after buying an additional 100,979 shares in the last quarter. 42.61% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://transcriptdaily.com/2018/02/25/aduro-biotech-adro-stock-price-up-6-5.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.